Advertisement

Drugs & Therapy Perspectives

, Volume 5, Issue 8, pp 14–16 | Cite as

Using drug utilisation review to assess the appropriateness of thrombolytic therapy

Drug Economics and Quality of Life
  • 4 Downloads

Keywords

Acute Myocardial Infarction Streptokinase Thrombolytic Therapy Alteplase Moclobemide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    McGlynn S. Criteria for drug usage review of thrombolytics in acute myocardial infarction. PharmacoEconomics 1995; 7: 25–38PubMedCrossRefGoogle Scholar
  2. 2.
    GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardio). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1988; 1: 397–401Google Scholar
  3. 3.
    ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349–59Google Scholar
  4. 4.
    Wilcox RG, Olsson CG, Skene AM, et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Lancet 1988; 2: 525–30PubMedCrossRefGoogle Scholar
  5. 5.
    AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988; 1: 545–9Google Scholar
  6. 6.
    Blackburn JL. Impact of drug usage review on drug utilisation. PharmacoEconomics 1993; 3: 14–21PubMedCrossRefGoogle Scholar
  7. 7.
    Stolar MH. Drug use review: operational definitions. Am J Hosp Pharm 1978; 35: 76–8PubMedGoogle Scholar
  8. 8.
    Sacristán JA, Soto J. Drug utilisation studies as tools in health economics. PharmacoEconomics 1994; 5: 299–312PubMedCrossRefGoogle Scholar
  9. 9.
    ASHP guidelines on the pharmacist’s role in drug use evaluation. Am J Hosp Pharm 1988; 45: 385–6Google Scholar
  10. 10.
    Fibrinolytic Therapy Trialist (FIT) Collaborative Group. Indications for fibrinolytic therapy in suspected myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311–21Google Scholar
  11. 11.
    Rubin RN. Choosing a thrombolytic agent in acute MI. Drug Ther 1992; 22: 17–32Google Scholar
  12. 12.
    Figueredo VM, Amidon TM, Wolfe CL. Thrombolysis after acute myocardial infarction. Postgrad Med 1994; 96: 30–40PubMedGoogle Scholar
  13. 13.
    Fendrick AM, Ridker PM, Bloom BS. Improved health benefits of increased use of thrombolytic therapy. Arch Intern Med 1994; 154: 1605–9PubMedCrossRefGoogle Scholar
  14. 14.
    Ketley D, Woods KL. Impact of clinical trials on clinical practice: example of thrombolysis for acute myocardial infarction. Lancet 1993; 342: 891–4PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1995

Personalised recommendations